从临床药理学角度探讨中药治疗急性脑梗死研究进展

Research progress on Chinese materia medica in treatment of acute cerebral infarction based on clinical pharmacology

卒中已成为造成人类死亡的第2位病因,除血管再通外,尚无有循证医学支持的有效药物。近年来,国内外对于急性脑梗死后外周血生物学标记物给予了极大的关注,从脑组织损伤、炎症反应、凝血/血栓形成、血管再生4个角度分类阐述与急性脑梗死预后紧密相关的临床药理学指标及中药应用于急性脑梗死的临床评价,以期为进一步阐释中药复杂成分的作用机制和研究开发治疗急性脑梗死的中药注射液大品种提供有意义的参考。

Stroke is the second cause of human death, while except the blood vessels recanalization, there is no effective drugs supported by evidence-based medicine. At home and abroad in recent years, a biological marker in peripheral blood after acute cerebral infarction attracted a lot of attention. This article explained the clinical pharmacological indexes closely related to the prognosis of acute cerebral infarction and clinical evaluation of Chinese materia medica （CMM） in treatment of acute cerebral infarction from four perspectives such as the injury of brain tissue, inflammation, blood coagulation/thrombosis, and vascular regeneration, in order to further explain the mechanism of action of complex components in CMM and to provide references for the research and development of CMM injection in treatment of acute cerebral infarction big varieties to provide meaningful reference.